Business
Research agreement with global biopharma partner
Research agreement with global biopharma partner.
About this update from Metir Plc
[{"type":"text","content":"\n \nRNS Number : 1543Z Microsaic Systems plc 13 December 2017 \n\n \n13 December 2017\nMicrosaic Systems plc\n(\"Microsaic\" or the \"Company\")\n \n \nMicrosaic signs new phase of research agreement with a global partner in biopharma\n \nMicrosaic Systems plc (AIM: MSYS), the developer of chip-based mass spectrometry instruments, announces that it has signed a research agreement extending its collaboration with a long standing global partner in the scale up and manufacture of biopharmaceutical drugs. This amendment to the agreement has been entered into following the successful completion of a collaboration stage contracted in a previous amendment announced on 7 April 2017. \n \nGlenn Tracey, CEO of Microsaic Systems plc, commented: \"We are delighted to agree this new phase of our collaboration with one of the foremost players in the global market for scientific instrumentation, which is in line with the Company's strategy to focus on application areas in bioprocessing and diagnostics. Since our previous announcement in April, in cooperation with the partner, we have demonstrated the technical feasibility of a specific biopharma application, and established the interest of end users. In this most recent contracted phase, which is expected to last into H2 2018, we will work closely with the partner to further integrate our MS technology with their world leading purification equipment. Our goal is that this will be followed by full product development and launch. If this goal is realised, we estimate that this product alone will represent a major commercial opportunity for Microsaic. Additionally, we will be evaluating other potential applications with this partner.\n \n\"I am pleased that with this extension and deepening of our collaboration, our partner is demonstrating confidence both in Microsaic's MS technology, and in the potential of miniature MS in the bioprocessing industry.\"\nThis announcement is released by Microsaic Systems plc and contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 (\"MAR\"), encompassing information relating to the agreement described herein, and is disclosed in accordance with the Company's obligations under Article 17 of MAR.\nFor the purposes of MAR and Article 2 of Commission Implementing Regulation (EU) 2...